Comparable Inhalers to Breo
The most directly comparable inhalers to Breo (fluticasone furoate/vilanterol) are Advair (fluticasone propionate/salmeterol) and Symbicort (budesonide/formoterol), both of which are ICS/LABA combinations that have demonstrated similar efficacy in improving lung function and reducing exacerbations 1.
Understanding Breo's Drug Class
Breo Ellipta contains fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-agonist), delivered as a once-daily dry powder inhaler 2. This places it in the ICS/LABA combination therapy class, which is recommended for patients with moderate to severe COPD or persistent asthma requiring combination therapy 1.
Direct Comparators
Advair (Fluticasone Propionate/Salmeterol)
Advair Diskus is the most studied comparator to Breo, with multiple head-to-head trials demonstrating comparable efficacy:
For COPD: Once-daily Breo 100/25 mcg showed similar or slightly better lung function improvements compared to twice-daily Advair 250/50 mcg or 500/50 mcg 3, 4. The treatment difference was statistically but not clinically significant in pooled analyses 3.
For Asthma: Once-daily Breo 100/25 mcg demonstrated similar efficacy to twice-daily Advair 250/50 mcg in improving lung function, asthma control, and quality of life 5.
Generic availability: Wixela Inhub is an FDA-approved generic substitute for Advair Diskus that has shown equivalent effectiveness and safety in real-world COPD patients 6.
Symbicort (Budesonide/Formoterol)
Symbicort is another well-established ICS/LABA combination that has been extensively studied:
Guidelines recognize both fluticasone/salmeterol and budesonide/formoterol as effective ICS/LABA combinations for reducing exacerbations 1.
A Cochrane meta-analysis evaluated 10 studies with fluticasone/salmeterol and 4 studies with budesonide/formoterol, finding both reduced exacerbations compared to long-acting bronchodilators alone 1.
Recent real-world data suggests budesonide/formoterol as MART (maintenance and reliever therapy) shows similar effectiveness to fluticasone furoate/vilanterol for asthma control 7.
Key Differences to Consider
Dosing Frequency
- Breo: Once-daily administration
- Advair and Symbicort: Twice-daily administration
The once-daily dosing of Breo may improve adherence in patients who struggle with twice-daily regimens 8, though this theoretical advantage hasn't been definitively proven to translate into better clinical outcomes.
Pneumonia Risk
All ICS/LABA combinations carry an increased risk of pneumonia 1. The Cochrane meta-analysis found a 4% increased risk of pneumonia with ICS/LABA combinations compared to long-acting bronchodilators alone 1. This risk appears similar across different ICS/LABA products, including Breo 8.
Device Considerations
- Breo: Ellipta dry powder inhaler
- Advair: Available as Diskus (dry powder) or HFA (metered-dose inhaler)
- Symbicort: Turbuhaler (dry powder) or pMDI
Patients with low inspiratory flow may benefit from metered-dose inhalers over dry powder devices 9.
Alternative Dual Bronchodilator Option
For patients who cannot tolerate or should avoid ICS, LABA/LAMA combinations (like umeclidinium/vilanterol or tiotropium/olodaterol) provide an alternative dual bronchodilator approach without corticosteroid exposure 10, 11. These may be particularly appropriate for patients at high risk for pneumonia or those without frequent exacerbations.
Clinical Decision Algorithm
Choose Breo when:
- Patient requires ICS/LABA combination therapy
- Once-daily dosing would improve adherence
- Patient can use dry powder inhaler effectively
Choose Advair when:
- Generic cost savings are priority (Wixela Inhub)
- Patient prefers twice-daily dosing
- Metered-dose inhaler option needed (Advair HFA)
Choose Symbicort when:
- MART strategy desired for asthma patients
- Patient has experience with this product
- Formulary or cost considerations favor it
All three options have comparable efficacy for the critical outcomes of lung function improvement and exacerbation reduction 1, 5, 3, 4.